On July 12, 2021 Patrys reported new data confirming its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross the blood-brain barrier (BBB) in animal models of primary brain cancer (Press release, Patrys, JUL 12, 2021, View Source [SID1234584770]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This data follows recent studies showing the deoxymab antibody fragment, PAT-DX1, is able to cross the BBB in animal models of primary and secondary brain cancer.

Most antibodies are unable to cross cell membranes or the blood-brain barrier, limiting their use in treating cancers of the brain. However, Dr James Hansen at Yale School of Medicine has shown the potential of Patrys’ lead deoxymab, PAT-DX1, for tackling these difficult-to-reach-and-treat cancers.

The Company plans to conduct follow up studies to compare the effects of both PAT-DX3 and PAT-DX1 on tumour reduction and survival in brain cancer.

Patrys CEO and MD, Dr James Campbell said:

We are very excited by this new discovery that opens up a range of development and partnering opportunities for Patrys around PAT-DX3. As PAT-DX3 shares a common mechanism of action with PAT-DX1, it is expected that it will also localise to both primary and secondary tumours in the brain and selectively kill cancer cells by blocking their DNA Damage Repair (DDR) systems.